Mallia and Northway Biotech Partner for Hair Loss Treatment Protein Manufacturing

Mallia Therapeutics and Northway Biotech announced their collaboration to develop and manufacture the soluble CD83 protein (sCD83), targeting hair loss treatment. This partnership aims to explore the alopecia market by offering a safe and effective topical treatment to stimulate hair follicle formation and promote sustained hair growth.

Northway Biotech will utilize its biologics manufacturing expertise to establish a production process for the recombinant sCD83 protein using the Pichia pastoris expression system. This includes the development of analytical methods and the production of a cGMP Drug Substance.

Dr. Manfred Groeppel from Mallia emphasized the importance of scaling research into treatment, while Prof. Dr. Alexander Steinkasserer noted sCD83's potential to redefine approaches to alopecia treatments.